Hologic, Inc. has completed its merger with Hopper Parent Inc., becoming a wholly owned subsidiary of the Blackstone and TPG-affiliated entity. Shareholders received $76.00 per share in cash and one contingent value right (CVR) per share, with total cash consideration for the transaction amounting to approximately $17.3 billion.

Hologic, Inc. has received all necessary regulatory approvals to complete its merger with affiliates of Blackstone Inc. and TPG Global, LLC. The transaction is expected to close on or about April 7, 2026, at which time President, CEO, and Chairman Stephen P. MacMillan will retire.

Hologic stockholders approved the merger agreement for the company's acquisition by Blackstone and TPG, receiving 178,777,739 votes in favor. While the merger passed, shareholders rejected the advisory compensation proposal for executive officers, which garnered 115,723,408 votes against. The transaction is expected to close in March or April 2026.

Hologic, Inc. announced its financial results for the first quarter ended December 27, 2025, via a press release issued on January 29, 2026. The filing also provides information regarding the company's proposed acquisition by affiliates of Blackstone Inc. and TPG Capital.

Hologic is supplementing its merger proxy statement to address shareholder litigation alleging disclosure deficiencies regarding its acquisition by Hopper Parent Inc. The filing also updates the company's illustrative equity value range to $66.67–$99.09 per share and notes that a voluntary recall of Brevera 9 Gauge Needles, which accounted for 4.7% of 2025 Breast Health revenue, may negatively impact 2026 contingent value right (CVR) milestones.